Investors eyeing a purchase of BioCryst Pharmaceuticals Inc (BCRX - Get Report) shares, but tentative about paying the going market price of $5.52/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the September put at the $4 strike, which has a bid at the time of this writing of 40 cents. Collecting that bid as the premium represents a 10% return against the $4 commitment, or a 18.9% annualized rate of return (at Stock Options Channel we call this the YieldBoost).Selling a put does not give an investor access to BCRX's upside potential the way owning shares would, because the put seller only ends up owning shares in the scenario where the contract is exercised. And the person on the other side of the contract would only benefit from exercising at the $4 strike if doing so produced a better outcome than selling at the going market price. ( Do options carry counterparty risk? This and six other common options myths debunked). So unless BioCryst Pharmaceuticals Inc sees its shares decline 27.4% and the contract is exercised (resulting in a cost basis of $3.60 per share before broker commissions, subtracting the 40 cents from $4), the only upside to the put seller is from collecting that premium for the 18.9% annualized rate of return. Below is a chart showing the trailing twelve month trading history for BioCryst Pharmaceuticals Inc, and highlighting in green where the $4 strike is located relative to that history: The chart above, and the stock's historical volatility, can be a helpful guide in combination with fundamental analysis to judge whether selling the September put at the $4 strike for the 18.9% annualized rate of return represents good reward for the risks. We calculate the trailing twelve month volatility for BioCryst Pharmaceuticals Inc (considering the last 251 trading day closing values as well as today's price of $5.52) to be 66%. For other put options contract ideas at the various different available expirations, visit the BCRX Stock Options page of StockOptionsChannel.com.
More from Stocks
Crown Castle International Expected to Earn 49 Cents a Share
Crown Castle International revenue expected to rise 7.5% to $1.5 billion.
Fulton Financial Shares Higher as Banking Firm Sets New $100 Million Buyback
The company completed a previous $100 million buyback announced in March.
Nvidia Shares Climb After Bank of America Increases Price Target
Bank of America's target is Wall Street's highest, Bloomberg reports, as the firm expressed optimism about the chipmaker's growth.